Infographic
Nerandomilast in Patients With Idiopathic Pulmonary Fibrosis
© 2025 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of First Report Managed Care or HMP Global, their employees, and affiliates.
Infographic
05/21/2026
The infographic summarizes 76-week study data from the phase 3 FIBRONEER-IPF trial to provide additional insights on lung function trends, disease progression, mortality risk, and safety outcomes over time with nerandomilast.
The infographic summarizes 76-week study data from the phase 3 FIBRONEER-IPF trial to provide additional insights on lung function trends, disease progression, mortality risk, and safety outcomes over time with nerandomilast.
The infographic summarizes...
05/21/2026
First Report Managed Care
White Papers
05/14/2026
Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease with significant clinical and economic burden and limited effective long-term treatment options. Nerandomilast, a selective PDE4B inhibitor, slows lung function decline...
Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease with significant clinical and economic burden and limited effective long-term treatment options. Nerandomilast, a selective PDE4B inhibitor, slows lung function decline...
Idiopathic pulmonary fibrosis...
05/14/2026
First Report Managed Care
Videos
12/10/2025
Saad Ashraf, MD
In the final chapter of our pulmonary fibrosis webinar series, Dr Saad Ashraf discussed FDA-approved nerandomilast and what its introduction means for clinicians, payers, and patients living with interstitial lung disease.
In the final chapter of our pulmonary fibrosis webinar series, Dr Saad Ashraf discussed FDA-approved nerandomilast and what its introduction means for clinicians, payers, and patients living with interstitial lung disease.
In the final chapter of our...
12/10/2025
First Report Managed Care
Videos
11/07/2025
Elizabeth Volkmann, MD, MS; Carole Tremonti, RN, MBA
As new therapies for idiopathic pulmonary fibrosis (IPF) emerge, healthcare stakeholders must navigate the balance between innovation and evidence-based coverage decisions. This webinar brings together clinical, regulatory, and payer...
As new therapies for idiopathic pulmonary fibrosis (IPF) emerge, healthcare stakeholders must navigate the balance between innovation and evidence-based coverage decisions. This webinar brings together clinical, regulatory, and payer...
As new therapies for idiopathic...
11/07/2025
First Report Managed Care